By Hendra Lukman 
A groundbreaking preliminary analysis suggests that individuals battling advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of initiating immunotherapy experienced a significant increase in survival time compared to those who did not receive the vaccine. This finding, presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, marks a pivotal moment in the decade-long quest to harness mRNA technology for cancer treatment, potentially paving the way for universal cancer vaccines.
Unexpected Synergy: mRNA Vaccines as Immune System Modulators
The research, a collaborative effort between scientists at the University of Florida (UF) and the University of Texas MD Anderson Cancer Center, posits that the immune-priming effects of mRNA COVID-19 vaccines may extend beyond viral defense to bolster the body’s fight against cancer when combined with immunotherapy. This unexpected synergy arises from the fundamental principle of mRNA technology: instructing cells to produce specific proteins. In the context of viral vaccines, this means creating spike proteins to elicit an immune response. However, the latest research suggests that the mere act of stimulating the immune system through mRNA technology, even without targeting a specific cancer protein, can create a potent anti-tumor effect.
"The implications are extraordinary — this could revolutionize the entire field of oncologic care," stated senior researcher Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and the Stop Children’s Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research. "We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients."
A Decade of mRNA Research Culminates in a Crucial Observation
The current findings build upon years of dedicated research into mRNA-based therapeutics. Dr. Sayour’s laboratory, for instance, has spent eight years refining the use of lipid nanoparticles with mRNA. This work, initially focused on developing cancer-specific mRNA vaccines, took an unexpected turn in July when researchers discovered that a broad immune stimulation, akin to fighting a viral infection, could be highly effective.
In preclinical studies using mouse models, an experimental "nonspecific" mRNA vaccine, similar in technology to COVID-19 vaccines but not targeting any specific virus or cancer, was paired with immune checkpoint inhibitors. These inhibitors are a class of drugs commonly used in cancer therapy to "release the brakes" on the immune system, enabling it to better recognize and attack cancer cells. The combination in mice demonstrated a robust antitumor response, turning previously unresponsive cancers into responsive ones and effectively thwarting tumor growth.
This breakthrough led Dr. Adam Grippin, M.D., Ph.D., a former UF researcher now with MD Anderson Cancer Center, to pose a critical question: could the readily available COVID-19 mRNA vaccines themselves offer a similar immune-boosting benefit to cancer patients undergoing immunotherapy?
Preliminary Analysis Reveals Significant Survival Gains
To investigate this hypothesis, the research team meticulously analyzed the anonymized medical records of over 1,000 patients treated at MD Anderson Cancer Center between 2019 and 2023. The study focused on patients diagnosed with advanced (Stage 3 and 4) non-small cell lung cancer and metastatic melanoma. These are cancers where immunotherapy is often a last resort, as patients at these stages frequently have exhausted other treatment options like radiation, surgery, and chemotherapy, and many do not respond well to immunotherapy alone.
The analysis revealed a striking pattern: patients who received a COVID-19 mRNA vaccine within a 100-day window before or after commencing immunotherapy treatment exhibited considerably longer median survival times than their counterparts who did not receive the vaccine.
Key Data Points from the Analysis:
- Advanced Lung Cancer Patients:
- 180 patients received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy.
- 704 patients received the same immunotherapy but did not receive the vaccine.
- Result: Median survival nearly doubled, increasing from 20.6 months to 37.3 months for vaccinated patients.
- Metastatic Melanoma Patients:
- 43 patients received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy.
- 167 patients received the same immunotherapy but did not receive the vaccine.
- Result: Median survival increased from 26.7 months to a range of 30 to 40 months. Importantly, at the time of data collection, some vaccinated patients were still alive, suggesting the potential for an even greater survival benefit as follow-up continues.
Notably, the study found no similar longevity improvements in patients who received non-mRNA vaccines such as those for pneumonia or influenza, underscoring the specific role of mRNA technology in this observed effect.
Mechanism of Action: A "Flare" for Immune Cells
Researchers hypothesize that the mRNA vaccine acts as a potent immune stimulant, essentially serving as a "flare" that redirects immune cells. "One of the mechanisms for how this works is when you give an mRNA vaccine, that acts as a flare that starts moving all of these immune cells from bad areas like the tumor to good areas like the lymph nodes," explained Dr. Sayour. This increased concentration of immune cells in lymph nodes, crucial sites for immune system activation, could then be more effectively mobilized by immunotherapy to target cancer.
The study’s findings are particularly encouraging for patients who, based on tumor biology and other indicators, were not expected to respond well to immunotherapy. In these cases, the observed survival improvements were most pronounced, suggesting that the mRNA vaccine can overcome resistance to standard treatments.
Broader Implications and Future Directions
The implications of these preliminary findings are profound, potentially reshaping the landscape of cancer care. Dr. Jeff Coller, Ph.D., a leading mRNA expert at Johns Hopkins University, commented on the significance of the results, noting that they highlight "yet another way Operation Warp Speed… continues to benefit lives in ‘unique and unexpected ways.’" He added, "The results from this study demonstrate how powerful mRNA medicines truly are and that they are revolutionizing our treatment of cancer."
While the current study is observational and requires confirmation through rigorous randomized clinical trials, its potential impact is undeniable. "Although not yet proven to be causal, this is the type of treatment benefit that we strive for and hope to see with therapeutic interventions — but rarely do," remarked Dr. Duane Mitchell, M.D., Ph.D., Dr. Grippin’s doctoral mentor and director of the UF Clinical and Translational Science Institute. "I think the urgency and importance of doing the confirmatory work can’t be overstated."
The next critical step is to initiate a large-scale clinical trial. The UF-led OneFlorida+ Clinical Research Network, a consortium of hospitals and clinics across multiple states, is poised to undertake this vital endeavor. "One of our key motivations at OneFlorida is to move discoveries from academic settings out into the real world and the places where patients get care," said Betsy Shenkman, Ph.D., who leads the consortium.
If confirmed through randomized trials, this research opens the door to developing even more advanced, non-specific universal cancer vaccines. Such vaccines, capable of enhancing immunotherapy across a broad spectrum of cancers, could offer patients invaluable time, a benefit that is immeasurable for those facing advanced disease.
"If this can double what we’re achieving currently, or even incrementally — 5%, 10% — that means a lot to those patients, especially if this can be leveraged across different cancers for different patients," Dr. Sayour emphasized.
A Testament to Scientific Innovation and Collaboration
The research was made possible through funding from the National Cancer Institute and various foundations, underscoring the critical role of sustained scientific investment. Additionally, the researchers involved, including Drs. Sayour, Grippin, and Mitchell, hold patents related to UF-developed mRNA vaccines, which are licensed by iOncologi Inc., a biotech company that originated as a spinout from UF. This entrepreneurial spirit further highlights the commitment to translating scientific discovery into tangible patient benefits.
The convergence of advanced cancer research with the rapid development of mRNA vaccine technology, spurred by the global COVID-19 pandemic, represents a remarkable testament to scientific innovation and the power of interdisciplinary collaboration. While further validation is essential, the preliminary findings offer a beacon of hope for millions of cancer patients worldwide, suggesting that the fight against cancer may be on the cusp of a revolutionary advancement.